ECOR Stock Forecast

ECOR Stock Forecast

ECOR Stock Forecast: The Average ECOR Stock Forecast for the next 12 months is $2.75


Latest Stock Price

ECOR Stock Forecast: Recent Performance

  • Last 5 Days – 18.3%
  • Last 1 Month – (-15.1%)
  • YTD – (-51.5%)

ECOR Stock Forecast: Latest News

  1. ElectroCore Distribution agreement with Joerns: ElectroCore announced an agreement with Joerns Healthcare (a healthcare technology and equipment company) to distribute and bill gamaCore sapphire (nVNS therapy – the only FDA-approved non-invasive headache treatment device), within a self-insured managed care organization.
  2. nVNS as a possible treatment for  TBI: electroCore announced last month that the nVNS (non-invasive vagus nerve stimulation) can be a possible treatment for TBI (Traumatic Brain Injury) and the data showcased that this can be a capable solution for TBI/Concussion. Their pre-clinical trial showed that nVNS has the potential to reduce the amount of brain injury, decrease anxiety and improve motor functioning ability, overall improving the neurobehavioural outcomes after the injury. NINDS (National Institute of Neurological Disorders and Stroke) agreed to fund their research further through an R21 grant of the University of Mexico. 
  3. electroCore issued 4 patents: electroCore has issued 4 patents for its technologies which included technologies related to nVNS. The four patents are “Mobile Phone for Treating a Patient with Dementia”, “Devices and Methods for Remote Therapy and Patient Monitoring”, “Electrical Nerve Stimulation to Treat Gastroparesis”, “Functional Dyspepsia, and Other Functional Gastrointestinal Disorders”, “Stimulator for Use with a Mobile Device”. These patents help in accelerating the nVNS therapy, by supporting their mobile platforms.

ECOR Stock Forecast: Latest Video

YouTube video

ECOR Stock Forecast: Q3 Results

  • The company’s total revenues were declared as $2 million, down 27.3% Y-o-Y.
  • Its gross profit was $1.7 million, up 51.7% Y-o-Y.
  • Operating expenses increased by 42.2% Y-o-Y and were reported as $7.3 million,
  • The company’s operating income decreased by 39.4% over a year and was reported as -$5.6 million.
  • Its net income was -$5.5 million, down 36.6% Y-o-Y.
  • Revenue per share was $0.03, up 29.9% Y-o-Y.
  • Diluted earnings per share (EPS) were declared as -$0.08, down 33.5% Y-o-Y.
  • Its EBIT was declared as -$5.6 million, down 39.4% Y-o-Y.
  • The forward PE ratio 1-year of the company is -$0.77.

ECOR Stock Forecast: Price target for the next 12 months

The average forecast for the next 12 months$2.75
HC Wainwright$2.75

ECOR Stock Forecast: Conclusion

Ecor stock has gone up by around 30% since its announcement of quarter 3 results. The company has strengthened its patent portfolio in this quarter and there is positive advancement in nVNS research on its potential to treat TBI (Traumatic Brain Injury), but the stock is accompanied by the risk of delisting from Nasdaq due to its price being less than $1. So, investors have to be mindful before investing.

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.

Vineet

Vineet

Vineet Agarwal is a trained technical analyst and avid stock trader. A graduate from a Top Technology Institute, Vineet carries out extensive technical and secondary research for this authored stock forecasts.